Jefferies Downgrades Summit Therapeutics to Hold, Lowers Price Target to $15

Benzinga Newsdesk www.benzinga.com Negative 92.6%

Neg 92.6% Neu 0% Pos 0%

Jefferies analyst Clara Dong downgrades Summit Therapeutics (NASDAQ:SMMT) from Buy to Hold and lowers the price target from $42 to $15.